Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - orphenadrine citrate, quantity: 100 mg - tablet, modified release - excipient ingredients: ethylcellulose; lactose monohydrate; magnesium stearate; colloidal anhydrous silica - relief of painful muscle spasm associated with fibrositis, whiplash injuries, torticollis, prolapsed intervertebral disc, strains, sprains and similar conditions. has also been shown to be of value in tension headache and persistent hiccup.

Ireland - English - HPRA (Health Products Regulatory Authority)

rosemont pharmaceuticals ltd - orphenadrine - oral solution - 50 mg/5ml

Australia - English - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - orphenadrine citrate, quantity: 35 mg; paracetamol, quantity: 450 mg - tablet, uncoated - excipient ingredients: pregelatinised maize starch; colloidal anhydrous silica; microcrystalline cellulose; magnesium stearate; gelatin - tension headache, occipital headaches associated with spasm of skeletal muscles in the region of the head and neck. acute and traumatic conditions of the limbs and trunk: sprains, strains, whiplash injuries, acute torticollis, prolapsed intervertebral disc.

New Zealand - English - Medsafe (Medicines Safety Authority)

seqirus (nz) ltd - orphenadrine hydrochloride 50mg; orphenadrine hydrochloride 50mg; orphenadrine hydrochloride 50mg - coated tablet - 50 mg - active: orphenadrine hydrochloride 50mg excipient: acacia gelatin lactose monohydrate polyvinyl acetate potato starch purified talc   shellac stearic acid sucrose   titanium dioxide white beeswax active: orphenadrine hydrochloride 50mg excipient: acacia   calcium carbonate calcium phosphate gelatin opaseal p-17-0200 opalux as 3026 yellow - contains tartrazine kaolin lactose monohydrate magnesium stearate maize starch opacode black s-1-27794 opaglos white 6000 purified talc stearic acid sucrose   titanium dioxide active: orphenadrine hydrochloride 50mg excipient: acacia   calcium carbonate calcium phosphate gelatin opaseal p-17-0200 opalux as 3026 yellow - contains tartrazine kaolin lactose monohydrate magnesium stearate maize starch opaglos white 6000 purified talc stearic acid sucrose   titanium dioxide - parkinson's disease, all forms of parkinsonism.

Canada - English - Health Canada

3m pharmaceuticals, a division of 3m canada company - orphenadrine citrate; acetylsalicylic acid; caffeine - tablet - 25mg; 385mg; 30mg - orphenadrine citrate 25mg; acetylsalicylic acid 385mg; caffeine 30mg - miscellaneous skeletal muscle relaxants

Canada - English - Health Canada

3m pharmaceuticals, a division of 3m canada company - orphenadrine citrate; acetylsalicylic acid; caffeine - tablet - 50mg; 770mg; 60mg - orphenadrine citrate 50mg; acetylsalicylic acid 770mg; caffeine 60mg - miscellaneous skeletal muscle relaxants

Canada - English - Health Canada

valeant canada lp / valeant canada s.e.c. - orphenadrine citrate - liquid - 30mg - orphenadrine citrate 30mg - miscellaneous skeletal muscle relaxants

Canada - English - Health Canada

valeant canada lp / valeant canada s.e.c. - orphenadrine citrate - tablet (extended-release) - 100mg - orphenadrine citrate 100mg - miscellaneous skeletal muscle relaxants

United States - English - NLM (National Library of Medicine)

poly pharmaceuticals, inc. - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - norgesic forte 50 mg/770mg/60 mg tablets are indicated in: - symptomatic relief of mild to moderate pain of acute musculoskeletal disorders. - the orphenadrine component is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. the mode of action of orphenadrine has not been clearly identified, but may be related to its analgesic properties. norgesic forte tablets do not directly relax tense skeletal muscles in man. the mode of action of orphenadrine has not been clearly identified, but may be related to its analgesic properties. norgesic forte tablets do not directly relax tense skeletal muscles in man. because of the mild anti-cholinergic effect of orphenadrine, norgesic forte tablets should not be used in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy, or obstructions at the bladder neck. norgesic forte tablets are also contraindicated in patients with myasthenia gravis and in patients known to be sensitive to aspirin or caffeine. the drug is contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.

United States - English - NLM (National Library of Medicine)

galt pharmaceuticals, llc - orphenadrine citrate (unii: x0a40n8i4s) (orphenadrine - unii:al805o9og9), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), caffeine (unii: 3g6a5w338e) (caffeine - unii:3g6a5w338e) - orphengesic forte (orphenadrine citrate, aspirin and caffeine 50 mg/ 770 mg/ 60 mg) tablets are indicated in: - symptomatic relief of mild to moderate pain of acute musculoskeletal disorders. - the orphenadrine component is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions. the mode of action of orphenadrine has not been clearly identified, but may be related to its analgesic properties. orphengesic forte tablets do not directly relax tense muscles in man. because of the mild anticholinergic effect of orphenadrine, orphengesic forte tablets should not be used in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy or obstructions at the bladder neck. orphengesic forte tablets are also contraindicated in patients with myasthenia gravis and in patients known to be sensitive to aspirin or caffeine. the drug is contraindicated in patients who have demonstrated a previous h